News
AKBA
0.4045
-0.12%
-0.0005
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Akebia Therapeutics Inc (NASDAQ: AKBA) announced initial findings from an investigator-sponsored study evaluating vadadustat for Acute Respiratory Distress Syndrome (ARDS) with COVID-19 and hypoxemia. Akebia said the drug failed the primary endpoint, as me...
Benzinga · 4d ago
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Akebia Therapeutics Sees FY22 Net Auryxia Product Revenue $170M-$175M
Akebia is increasing its net product revenue guidance for Auryxia to $170 - $175 million for fiscal year 2022, raising both the top and bottom end of the guidance range
Benzinga · 5d ago
Akebia Therapeutics Q2 EPS $0.15 Beats $(0.31) Estimate, Sales $126.76M Beat $49.73M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $(0.31) by 148.39 percent. This is a 129.41 percent increase over losses of $(0.51) per share
Benzinga · 5d ago
Akebia Therapeutics: Q2 Earnings Insights
Akebia Therapeutics (NASDAQ:AKBA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 5d ago
Akebia Therapeutics Announces Initial Findings From Investigator-Sponsored Clinical Study Evaluating Vadadustat For Prevention And Treatment Of Acute Respiratory Distress Syndrome (ARDS) In Subjects With COVID-19 And Hypoxemia (VSTAT)
 Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced initial findings from an
Benzinga · 5d ago
Akebia GAAP EPS of $0.15 beats by $0.48, revenue of $126.76M beats by $77.06M
Akebia press release (...
Seekingalpha · 5d ago
Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced initial findings from an investigator-sponsored study evaluating vadadustat, Akebia's investig...
PR Newswire · 5d ago
-- Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q2 Revenue $126.8M
-- Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q2 Revenue $126.8M
MT Newswires · 5d ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 26,000 shares of Akebia's common stock on...
PR Newswire · 08/02 20:05
Akebia Therapeutics to Report Second Quarter Financial Results
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2022 on Thursday, ...
PR Newswire · 07/26 12:00
Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?
Investor Place · 07/01 16:02
Wall Street Set for Losses as Recession Fears Linger
MT Newswires · 07/01 09:14
BRIEF-Akebia Therapeutics Regaining Rights To Vadadustat In The United States, Europe, China And Access Consortium Countries Upon Termination Of Collaboration And License Agreements With Otsuka
BRIEF-Akebia Therapeutics Regaining Rights To Vadadustat In The United States, Europe, China And Access Consortium Countries Upon Termination Of Collaboration And License Agreements With Otsuka
Reuters · 06/30 22:01
Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Akebia Therapeutics (NASDAQ:AKBA) on Thursday <a href="...
Seekingalpha · 06/30 20:23
Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration a...
PR Newswire · 06/30 20:05
Akebia to Get $55 Million Settlement Fee After Ending Vadadustat Deal with Otsuka; Stock Up 35% After-Hours
MT Newswires · 06/30 16:35
Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News
Investor Place · 06/29 17:42
18 Stocks Moving in Thursday's Pre-Market Session
Gainers View, Inc. (NASDAQ: VIEW) rose 18.5% to $2.05 in pre-market trading after declining 5% on Wednesday.
Benzinga · 06/09 10:13
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.